Tempus, a company focused on personalized oncology care, collects and analyzes large-scale databases of molecular and clinical information to support physicians treating cancer patients.
Under the agreement, Tempus will use its Tempus O platform to structure patient data from Vanderbilt-Ingram Cancer Center’s EHR. The company will also provide the cancer center with next generation sequencing and analysis services to identify actionable gene alterations.
“Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient’s cancer and its genetic and molecular drivers, with a goal of improving patient outcomes,” said Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center.
More articles on data analytics & precision medicine:
Microsoft, Google venture arms invest in genomic information startup DNAnexus
Baptist Health South Florida taps health tech startup for precision cancer care
4 questions with PotentiaMetrics CEO Robert Palmer on personalized healthcare
